Long Term Documentation of the Safety and Efficacy as Well as the Effects on Work Productivity in Patients With Moderate to Severe Plaque Psoriasis Treated With HUMIRA (Adalimumab) in Routine Clinical Practice (LOTOS)
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms LOTOS
- Sponsors Abbott Laboratories; AbbVie
- 30 Jan 2017 Planned End Date changed from 1 Oct 2020 to 1 Jan 2021.
- 30 Jan 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Jan 2021.
- 01 Aug 2016 Planned number of patients changed from 5500 to 3000.